Modern concepts of pleiotropic effects of semaglutide in a wide population of patients

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Peculiarity of modern hypoglycemic therapy is the effect on multiple pathogenetic targets and presence of a wide range of glycemic and non-glycemic effects, opening up new opportunities in achieving long-term results in type 2 diabetes mellitus (T2DM) treatment. An innovative group of drugs in T2DM treatment are glucagon-like peptide-1 receptor agonists, some of which are registered for the treatment of obesity. Thus, the effect of semaglutide combines high efficacy in terms of metabolic control and weight loss with serious cardio- and nephroprotective effects, as well as an effect on increasing life expectancy in patients with T2DM and obesity. The study of the pleiotropic properties of glucagon-like peptide-1 receptor agonists is actively ongoing, and new data allow us to specify focus groups and principles of a personalized approach to prescribing drugs in this group.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Tatyana Demidova

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University)

Email: t.y.demidova@gmail.com
ORCID iD: 0000-0001-6385-540X
SPIN-код: 9600-9796

MD, Dr. Sci. (Medicine), professor, head of the Department of endocrinology of the Institute of Clinical Medicine

Ресей, 117513, Moscow, 1/6 Ostrovityanova St.

Anna Teplova

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University)

Хат алмасуға жауапты Автор.
Email: anna_kochina_@mail.ru
ORCID iD: 0000-0002-6826-5924
SPIN-код: 2067-1320

MD, assistant at the Department of endocrinology of the Institute of Clinical Medicine

Ресей, 117513, Moscow, 1/6 Ostrovityanova St.

Maryam Izmailova

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University)

Email: maremizm@gmail.com
ORCID iD: 0000-0002-1385-0245
SPIN-код: 7882-8307

MD, assistant at the Department of endocrinology of the Institute of Clinical Medicine

Ресей, 117513, Moscow, 1/6 Ostrovityanova St.

Әдебиет тізімі

  1. Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:645563.PMID: 34305810. PMCID: PMC8294388. https://doi.org/10.3389/fendo.2021.645563
  2. Мкртумян А.М., Маркова Т.Н., Мищенко Н.К. Анализ сердечно-сосудистой безопасности современных сахароснижающих препаратов. Кардиология. 2019;59(7):76–83. [Mkrtumyan AM, Markova TN, Mishchenko NK. Analysis of cardiovascular safety of novel glucose-lowering medications. Kardiologiya = Cardiology. 2019;59(7):76–83 (In Russ.)].EDN: UZCOSK. https://doi.org/10.18087/cardio.2019.7.10267
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.PMID: 37952131. https://doi.org/10.1056/NEJMoa2307563
  4. Withaar C, Meems LMG, Nollet EE, Schouten EM, Schroeder MA, Knudsen LB et al. The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF. JACC Basic Transl Sci. 2023;8(10):1298–1314.PMID: 38094687. PMCID: PMC10714176. https://doi.org/10.1016/j.jacbts.2023.05.012
  5. Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R et al. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. 2024;11:1398059.PMID: 38742021. PMCID: PMC11090168. https://doi.org/10.3389/fnut.2024.1398059
  6. Шамхалова М.Ш., Скляник И.А., Шестакова М.В. Нефропротективный потенциал агонистов рецепторов глюкагоноподобного пептида 1. Сахарный диабет. 2020;23(1):56–64. [Shamkhalova MSh, Sklyanik IA, Shestakova MV. Nephroprotective potential of glucagon-like peptide-1 receptor agonists. Sakharnyy diabet = Diabetes Mellitus. 2020;23(1):56–64 (In Russ.)].EDN: QEZDWA. https://doi.org/10.14341/DM12379
  7. Демидова Т.Ю., Титова В.В., Измайлова М.Я. Преимущества агонистов рецепторов глюкагоноподобного пептида-1 в лечении пациентов с сахарным диабетом 2-го типа. Терапевтический архив. 2023;95(10):876–880. [Demidova TYu, Titova VV, Izmailova MYa. Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review. Terapevticheskiy arkhiv = Therapeutic Archive. 2023;95(10):876–880 (In Russ.)].EDN: SCTILP. https://doi.org/10.26442/00403660.2023.10.202425
  8. Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Am J Prev Cardiol. 2023;14:100502.PMID: 37313358. PMCID: PMC10258236. https://doi.org/10.1016/j.ajpc.2023.100502
  9. Манкиева Э.Г., Кухарева Е.И. Неалкогольная жировая болезнь печени у пациентов с сахарным диабетом 2-го типа. Доказательная гастроэнтерология. 2023;12(4):103–108. [Mankieva EG, Kukhareva EI. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Dokazatel’naya gastroenterologiya = Russian Journal of Evidence-Based Gastroenterology. 2023;12(4):103–108 (In Russ.)].EDN: PRZUZF. https://doi.org/10.17116/dokgastro202312041103
  10. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.PMID: 26707365. https://doi.org/10.1002/hep.28431
  11. Суплотова Л.А., Федорова А.И., Кульмаметова Д.С., Душина Т.С., Макарова О.Б. Перспективы использования препаратов группы агонистов рецепторов глюкагоноподобного пептида 1 в лечении неалкогольной жировой болезни печени. Медицинский совет. 2022;16(23):148–155. [Suplotova LA, Fedorova AI, Kulmametova DS, Dushina TS, Makarova OB. Prospects for the use of drugs from the group of agonists of glucagon-like peptide-1 receptors in the treatment of non-alcoholic fatty liver disease. Meditsinskiy sovet = Medical Council. 2022;16(23):148–155 (In Russ.)].EDN: OIZPKQ. https://doi.org/10.21518/2079-701X-2022-16-23-148-155
  12. Armstrong MJ, Houlihan DD, Rowe IA, Clausen WHO, Elbrønd B, Gough SCL et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther. 2013;37(2):234–42.PMID: 23163663. https://doi.org/10.1111/apt.12149
  13. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.PMID: 27062661. https://doi.org/10.1016/j.jhep.2015.11.004
  14. Blaslov K, Zibar K, Bulum T, Duvnjak L. Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients. Clin Res Hepatol Gastroenterol. 2014;38(3):e61–e63.PMID: 24315013. https://doi.org/10.1016/j.clinre.2013.10.013
  15. Южакова Е.В., Шанько Ж.Е., Смирнова Е.Н. Гепатотропные эффекты сахароснижающих препаратов: фокус на неалкогольную жировую болезнь печени. Экспериментальная и клиническая гастроэнтерология. 2023;(6):121–129. [Yuzhakova EV, Shanko ZhE, Smirnova EN. Hepatotropc effects of glucose-lowering drugs: Non-alcoholic fatty liver disease in focus. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2023;(6):121–129 (In Russ.)].EDN: LLWYZI. https://doi.org/10.31146/1682-8658-ecg-214-6-121-129
  16. Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives. Int J Mol Sci. 2023;24(2):1703.PMID: 36675217. PMCID: PMC9865319. https://doi.org/10.3390/ijms24021703
  17. Lin K, Dong C, Zhao B, Zhou B, Yang L. Glucagon-like peptide-1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism. MedComm (2020). 2023;4(6):e416.PMID: 38020719. PMCID: PMC10661313. https://doi.org/10.1002/mco2.416
  18. Kato S, Sato T, Fujita H, Kawatani M, Yamada Y. Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. Sci Rep. 2021;11(1):9167.PMID: 33911125. PMCID: PMC8080802. https://doi.org/10.1038/s41598-021-88612-x
  19. Zeng Y, Wu Y, Zhang Q, Xiao X. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. mBio. 2024;15(1):e0203223.PMID: 38055342. PMCID: PMC10790698. https://doi.org/10.1128/mbio.02032-23
  20. Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.PMID: 39289339. PMCID: PMC11408715. https://doi.org/10.1038/s41392-024-01931-z
  21. Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8(12):e170671.PMID: 37192005. PMCID: PMC10371247. https://doi.org/10.1172/jci.insight.170671
  22. Aranas C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Sköldheden SB et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642.PMID: 37295046. PMCID: PMC10363436. https://doi.org/10.1016/j.ebiom.2023.104642
  23. Salles GN, Calió ML, Hölscher C, Pacheco-Soares C, Porcionatto M, Lobo AO. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer’s disease. Neuropharmacology. 2020;162:107813.PMID: 31628935. https://doi.org/10.1016/j.neuropharm.2019.107813
  24. Ишмуратова А.Н., Абрамов М.А., Кузнецов К.О., Иванюта М.В., Шакирова З.Ф., Китапова А.И. с соавт. Роль противодиабетических препаратов в терапии болезни Альцгеймера: систематический обзор. Проблемы эндокринологии. 2023;69(5):73–83. [Ishmuratova AN, Abramov MA, Kuznetsov KO, Ivanyuta MV, Shakirova ZF, Kitapova AI et al. The role of antidiabetic drugs in the treatment of Alzheimer’s disease: Systematic review. Problemy endokrinologii = Problems of Endocrinology. 2023;69(5):73–83 (In Russ.)].EDN: RHLRQI. https://doi.org/10.14341/probl13183
  25. Sass MR, Danielsen AA, Köhler-Forsberg O, Storgaard H, Knop FK, Nielsen MØ et al. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: Study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). BMJ Open. 2023;13(1):e068652.PMID: 36720576. PMCID: PMC9890830. https://doi.org/10.1136/bmjopen-2022-068652
  26. Chen X, Zhao P, Wang W, Guo L, Pan Q. The antidepressant effects of GLP-1 receptor agonists: A systematic review and meta-analysis. Am J Geriatr Psychiatry. 2024;32(1):117–27.PMID: 37684186. https://doi.org/10.1016/j.jagp.2023.08.010
  27. Tipa RO, Balan D-G, Georgescu M-T, Ignat LA, Vacaroiu IA, Georgescu DE et al. A systematic review of smaglutide’s influence on cognitive function in preclinical animal models and cell-line studies. Int J Mol Sci. 2024;25(9):4972.PMID: 38732190. PMCID: PMC11084700. https://doi.org/10.3390/ijms25094972
  28. Власов Т.Д., Симаненкова А.В., Дора С.В., Шляхто Е.В. Механизмы нейропротективного действия инкретиномиметиков. Сахарный диабет. 2016;19(1):16–23. [Vlasov TD, Simanenkova AV, Dora SV, Shlyakhto EV. Mechanisms of neuroprotective action of incretin mimetics. Sakharnyy diabet = Diabetes Mellitus. 2016;19(1):16–23 (In Russ.)].EDN: VMCMWP. https://doi.org/10.14341/DM7192
  29. Кокин А.С., Суплотова Л.А., Душина Т.С., Макарова О.Б. Нейропротективный потенциал агонистов рецепторов глюкагоноподобного пептида 1-го типа. Медицинский совет. 2023;17(9):40–46. [Kokin AS, Suplotova LA, Dushina TS, Makarova OB. Neuroprotective potential of incretinomimetics. Meditsinskiy sovet = Medical Council. 2023;17(9):40–46 (In Russ.)].EDN: HNLVLP. https://doi.org/10.21518/ms2023-159
  30. Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2024;184(2):144–52.PMID: 38079178. PMCID: PMC10714281. https://doi.org/10.1001/jamainternmed.2023.6663
  31. Szczesnowicz A, Szeliga A, Niwczyk O, Bala G, Meczekalski B. Do GLP-1 analogs have a place in the treatment of PCOS? New Insights and Promising Therapies. J Clin Med. 2023;12(18):5915.PMID: 37762856. PMCID: PMC10532286. https://doi.org/10.3390/jcm12185915
  32. Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: A multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024;14(4):e083550.PMID: 38663923. PMCID: PMC11043712. https://doi.org/10.1136/bmjopen-2023-083550

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Main cardioprotective effects of glucagon-like peptide-1 receptor agonists

Жүктеу (124KB)
Метадеректер
3. Fig. 2. Protective effects of glucagon-like peptide-1 receptor agonists against metabolically associated fatty liver disease

Жүктеу (130KB)
Метадеректер
4. Fig. 3. Neuroprotective properties of glucagon-like peptide-1 receptor agonists

Жүктеу (177KB)
Метадеректер

© Bionika Media, 2025